Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients

Fig. 1

Flowchart of the patient selection process. Among the 331 patients who received neoadjuvant therapy and subsequent resection, patients with no assessment of carbohydrate antigen 19–9 (CA19–9) levels before or after surgery or with a total bilirubin level > 2.0 mg/dL were excluded. The remaining 240 patients were eligible and divided into three groups, the Normal group (sustained decreased CA19–9 levels ≤37 U/ml before and after neoadjuvant therapy), the Responder group (initial high levels that decreased to ≤37 U/ml after neoadjuvant therapy, and the Non-responder group (elevated level > 37 U/ml after neoadjuvant therapy)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us